FDA expands approval of cystic fibrosis treatment to include pediatric patients as young as 6 years old

The U.S. Food and Drug Administration today expanded the indication for Symdeko (a combination of tezacaftor/ivacaftor) tablets for treatment of pediatric patients ages 6 years and older with cystic fibrosis who have certain genetic mutations.

From https://www.news-medical.net/news/20190622/FDA-expands-approval-of-cystic-fibrosis-treatment-to-include-pediatric-patients-as-young-as-6-years-old.aspx

from
https://healthnews010.wordpress.com/2019/06/24/fda-expands-approval-of-cystic-fibrosis-treatment-to-include-pediatric-patients-as-young-as-6-years-old/

from https://jamesjohnson10.blogspot.com/2019/06/fda-expands-approval-of-cystic-fibrosis.html

from
https://jamesjohnson101.tumblr.com/post/185809627228

From https://judywatson1.blogspot.com/2019/06/fda-expands-approval-of-cystic-fibrosis.html

from
https://judywatson1.wordpress.com/2019/06/24/fda-expands-approval-of-cystic-fibrosis-treatment-to-include-pediatric-patients-as-young-as-6-years-old/